Carnitine in the treatment of valproic acid-induced toxicity.
about
Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acidN-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocolHigh-flux hemodialysis and levocarnitine in the treatment of severe valproic Acid intoxicationValproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts.Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen.A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.Extracorporeal elimination in acute valproic acid poisoning.Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl.Favorable results after conservative management of 316 valproate intoxicated patients.The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting.Valproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitineN-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.Effects of valproic acid on organic acid metabolism in children: a metabolic profiling studyNovel Vitamin K analogs suppress seizures in zebrafish and mouse models of epilepsy.An Update on Drug-induced Liver Injury.Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicityA pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.Valproate semisodium ER for migraine and cluster headache prophylaxis.Enzymology of the carnitine biosynthesis pathway.Review article: drug-induced liver injury in clinical practice.Animal models of idiosyncratic drug-induced liver injury--current status.Mitochondrial disease and epilepsy.Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.A new perspective on the importance of glycine conjugation in the metabolism of aromatic acids.Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.Sodium valproate-related hyperammonaemic encephalopathy.Defining 'nutraceuticals': neither nutritious nor pharmaceutical.The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.l-carnitine protects human hepatocytes from oxidative stress-induced toxicity through Akt-mediated activation of Nrf2 signaling pathway.Antidote availability in the municipality of Campinas, São Paulo, Brazil.Neurotoxicity of Ammonia.L-Arginine in the treatment of valproate overdose - five clinical cases.Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha.The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.Valproate Induced Delirium due to Hyperammonemia in a Case of Acute Mania: A Diagnostic DilemmaValproate-induced hyperammonemic encephalopathy: A reminder of rare complication of valproate.Posterior reversible encephalopathy syndrome in a survivor of valproate-induced acute liver failure: a case report.Valproic Acid-induced myoclonus in a demented patient: a case report.Carnitine deficiency and its possible risk factors in TB patients: first report.
P2860
Q21261395-3226A04B-0396-4108-95FC-40B45742F325Q27014948-7312155A-9EB4-45C1-9A0C-14BB858F53EDQ33408334-3B4CC74F-11BF-4D7B-8647-4A69D5D69565Q33581698-FA26D80E-5747-46A9-838E-E1F8C2CF7533Q33804773-0E67AAF5-47B0-4178-8477-F513692E31AAQ34392818-3963B5F2-C583-4952-9EDB-9CE70F279922Q34785900-40C32519-38D2-4495-978F-3D1892D36BB5Q34995723-9EE0BEF5-3FD2-4473-B359-725657683EBCQ35748734-00BC4F2D-C49A-41C0-BE9A-51E31D6F4257Q36263134-CCDCCC55-5156-4401-B40A-38F39E8CA790Q36307063-421320B3-F1E9-4787-9222-979CFCE3F7FDQ36891327-B570E4A7-8D3F-4ED1-AB99-4C84DA9E32E6Q36924709-882AB771-2AF4-4A2A-9D92-D8AF6E96BD38Q37294747-1E22EA71-2823-4F09-A00B-C9448DC9A4B3Q37521578-AE818B69-8F0D-4257-BCF8-8FF09164A037Q37613520-C57087F3-B1D0-40C9-A899-731500E399B0Q37656707-5F6D7FFA-7FB0-4AD2-B465-12162B98D9EFQ37686306-8373AABD-5F7A-4C30-935F-8E65EF5343C7Q37713736-BB24A223-237E-4BC3-8E12-5982DF733268Q37715879-26B14CCE-3A54-4443-8BA1-7EA02A354807Q37726069-FB01D2D0-E68F-4765-BC6E-BD94477B36AAQ37897219-AC4EDC6E-FCB1-4A2C-B060-8F30F7CD397FQ37979255-AD9E0219-E479-4275-9739-39F709572BE4Q38180728-16655F59-A86E-40C2-95EC-39321A6658DDQ38206257-DF806B0F-AD0A-4460-B195-135A0DB7D184Q38464083-D70B62D7-0C79-4BF8-A22B-6F0698F0AC6FQ38767317-97877624-7BA9-4550-8FD6-B020FE53B800Q38780015-648F41F5-2FE7-4BBD-88E0-9BF6004300D0Q38782421-CD9FF0D9-9BDD-422D-AD7D-CC241A8F666AQ38793210-BE2C4AD1-EC40-4B23-B139-22E95B6AEC48Q38903168-67D84E5A-B78E-484E-A9D9-FB861D50BE03Q38910515-B9494C8B-472E-468D-9638-C8148937AE28Q38983752-04A76FAB-0161-447E-B2CC-37CC616DA606Q39376036-32E44F94-8483-4B3F-91D5-21D2D95188C7Q39608766-7C898F78-DC5B-4E26-93B8-5273E0A5FB44Q40833111-0624F7DD-31A7-49FF-BB48-5B385C179067Q42010705-8FC43DA4-39E3-403B-BEFE-3D21187A726BQ42091278-883A364E-BA4D-4426-BFA2-6EC46F6E17BFQ42175879-7366539A-C467-495B-B540-49AFFFE73CB9Q42249006-917DDCE6-B50E-40BA-B636-7C3C01FA2D0B
P2860
Carnitine in the treatment of valproic acid-induced toxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Carnitine in the treatment of valproic acid-induced toxicity.
@en
Carnitine in the treatment of valproic acid-induced toxicity.
@nl
type
label
Carnitine in the treatment of valproic acid-induced toxicity.
@en
Carnitine in the treatment of valproic acid-induced toxicity.
@nl
prefLabel
Carnitine in the treatment of valproic acid-induced toxicity.
@en
Carnitine in the treatment of valproic acid-induced toxicity.
@nl
P2860
P1433
P1476
Carnitine in the treatment of valproic acid-induced toxicity.
@en
P2093
Philippe E R Lheureux
Philippe Hantson
P2860
P304
P356
10.1080/15563650902752376
P407
P577
2009-02-01T00:00:00Z